ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies
Immunitybio Inc IBRX
$7.76
▼ -3.00%
($-0.24)
Open
$7.96
Prev Close
$8.00
Day Range
$7.33 – $7.96
52W Range
$1.95 – $12.43
Market Cap
$8.14B
Beta
0.14
EPS (TTM)
$-0.39
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-07-28 |
| Shares Out. | 1,028,110,000 |
| Website | immunitybio.com/ ↗ |
| Phone | 13026587581 |
Immunitybio Inc is a publicly traded company under the ticker symbol IBRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-05-01)
📰 Latest News for IBRX
ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM
ImmunityBio Announces Results From Two ITC Analyses Presented At 2026 AUA Annual Meeting Evaluating Nogapendekin Alfa inbakicept-pmln Plus BCG
ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership
ImmunityBio Secures Five US Patents Covering Combination Of IL-15 Receptor Agonist ANKTIVA With Bacillus Calmette-Guérin For Treatment Of Cancer
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
Reported Saturday, ImmunityBio Secures Exclusive US Rights To Tokyo-172 BCG After Phase 3 Trial Shows Non-Inferior Efficacy To TICE BCG
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States